Beatrice C. Cianciotti

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Editorial: Safety and efficacy of CRISPR/Cas-based genome editing tools: applications and considerations in cell and gene therapy.

Editorial: Safety and efficacy of CRISPR/Cas-based genome editing tools: applications and considerations in cell and gene therapy.

Journal: Frontiers in immunology

Published: February 12, 2026

Regulatory T cell depletion promotes myeloid cell activation and glioblastoma response to anti-PD1 and tumor-targeting antibodies.

Regulatory T cell depletion promotes myeloid cell activation and glioblastoma response to anti-PD1 and tumor-targeting antibodies.

Journal: Immunity

Published: May 30, 2025

T Cell Features in Glioblastoma May Guide Therapeutic Strategies to Overcome Microenvironment Immunosuppression.

T Cell Features in Glioblastoma May Guide Therapeutic Strategies to Overcome Microenvironment Immunosuppression.

Journal: Cancers

Published: December 28, 2023

Harnessing T cell exhaustion and trogocytosis to isolate patient-derived tumor-specific TCR.

Harnessing T cell exhaustion and trogocytosis to isolate patient-derived tumor-specific TCR.

Journal: Science advances

Published: December 01, 2023

TIM-3, LAG-3, or 2B4 gene disruptions increase the anti-tumor response of engineered T cells.

TIM-3, LAG-3, or 2B4 gene disruptions increase the anti-tumor response of engineered T cells.

Journal: Frontiers in immunology

Published: October 10, 2023

Regulatory T cell depletion promotes myeloid cell activation and glioblastoma response to anti-PD1 and tumor-targeting antibodies.

Regulatory T cell depletion promotes myeloid cell activation and glioblastoma response to anti-PD1 and tumor-targeting antibodies.

Journal: Immunity

Published: June 26, 2023

Revealing and harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells.

Revealing and harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells.

Journal: Gut

Published: June 14, 2022

CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function.

CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function.

Journal: Science translational medicine

Published: February 09, 2022

Flow cytometry data mining by cytoChain identifies determinants of exhaustion and stemness in TCR-engineered T cells.

Flow cytometry data mining by cytoChain identifies determinants of exhaustion and stemness in TCR-engineered T cells.

Journal: European journal of immunology

Published: December 03, 2020

TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals.

TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals.

Journal: Frontiers in immunology

Published: April 08, 2020

CD4+ Memory Stem T Cells Recognizing Citrullinated Epitopes Are Expanded in Patients With Rheumatoid Arthritis and Sensitive to Tumor Necrosis Factor Blockade.

CD4+ Memory Stem T Cells Recognizing Citrullinated Epitopes Are Expanded in Patients With Rheumatoid Arthritis and Sensitive to Tumor Necrosis Factor Blockade.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: August 24, 2018

Tailored chemokine receptor modification improves homing of adoptive therapy T cells in a spontaneous tumor model.

Tailored chemokine receptor modification improves homing of adoptive therapy T cells in a spontaneous tumor model.

Journal: Oncotarget

Published: September 13, 2015

Showing 1-12 of 13

Last Updated: 09/26/2026